

# Organic & Biomolecular Chemistry

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



## Organic &amp; Biomolecular Chemistry

Paper

## Synthesis of $sp^3$ -rich Scaffolds for Molecular Libraries through Complexity-Generating Cascade Reactions

T. Flagstad,<sup>ab</sup> G. Min,<sup>ab</sup> K. Bonnet,<sup>c</sup> R. Morgentin,<sup>c</sup> D. Roche,<sup>c</sup> M. H. Clausen<sup>\*ab</sup> and T. E. Nielsen<sup>\*ad</sup>

Received 00th January 20xx,  
Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

www.rsc.org/


An efficient strategy for the synthesis of complex small molecules from simple building blocks is presented. Key steps of the strategy include tandem Petasis and Diels-Alder reactions, and divergent complexity-generating cyclization cascades from a key dialdehyde intermediate. The synthesis methodology is validated through the synthesis of a representative compound set, which has been used in the production of 1617 molecules for the European Lead Factory.

### Introduction

Small organic molecules are essential for the treatment of many diseases and constitute most medicines marketed today. The development of high-throughput screening (HTS) has enabled the extremely rapid biological evaluation of large collections of small organic molecules. However, despite advances in HTS technologies and general access to large molecular libraries, the annual number of approved small-molecule drugs has been declining for years.<sup>1</sup> Growing evidence now suggests that many existing compound collections are inadequate in the search for new molecular entities capable of interacting with complex biological targets.<sup>2</sup> Traditional compound collections are typically composed of flat molecules with a high degree of  $sp^2$ -hybridization and only few stereocenters.<sup>3</sup> These compound collections are commonly synthesized using classical combinatorial chemistry methods, powered by the development of effective  $sp^2$ - $sp^2$  coupling reactions, which have been widely exploited in the last decades. The routine synthesis of complex  $sp^3$ -rich molecules with control of stereochemistry remains elusive and poses a substantial challenge for library production.<sup>4,5</sup> Here, we report a strategy towards a screening library containing molecules with a relatively high degree of  $sp^3$  hybridization. In general, contributions to the European Lead Factory from the public consortium have a significantly higher fraction of  $sp^3$  compared to commercial compound collections<sup>4</sup>.

### Results and Discussion

In this work, we wish to present a strategy for the efficient formation of two novel scaffolds, each containing four stereogenic centers, including a quaternary center, applicable to molecular library production. The approach starts with a Petasis 3-component reaction<sup>6</sup> of salicylic aldehyde, allyl amine and 2-furyl boronic acid derivatives to form an aminophenol, which upon exposure to elevated temperatures undergoes an intramolecular Diels-Alder reaction<sup>7,8</sup> (Figure 1). The Diels-Alder product may then undergo oxidative cleavage to form a key dialdehyde intermediate, which can be reduced and used in a Mitsunobu<sup>9</sup> cascade reaction (library A), or participate in a reductive cyclisation with amines (library B).



**Figure 1.** Synthesis strategies for the generation of two distinct and complex  $sp^3$ -rich scaffolds (A and B), based on complexity-generating reactions from readily available starting materials.

For library development, it was decided to use *N*-allylbenzylamine as the amine component to enable late stage functionalization of the resulting scaffolds through benzyl deprotection and appendage modification of the resulting

<sup>a</sup> Department of Chemistry, Technical University of Denmark, DK-2800 Kgs. Lyngby, Denmark. E-mail: [ten@kemi.dtu.dk](mailto:ten@kemi.dtu.dk), [mhc@kemi.dtu.dk](mailto:mhc@kemi.dtu.dk)


<sup>b</sup> Center for Nanomedicine and Theranostics, Technical University of Denmark, DK-2800 Kgs. Lyngby, Denmark

<sup>c</sup> EDELIRIS, 115 Avenue Lacassagne, F-69003, France

Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/x0xx00000x

<sup>d</sup> Singapore Centre on Environmental Life Sciences Engineering, Nanyang Technological University, Singapore 637551, Singapore.

secondary amine. Two 2-hydroxy benzaldehydes were used in the tandem Petasis/Diels-Alder sequence, which provided the desired products **1a** and **1b** as single diastereoisomers in high yield on a 90 gram scale (85% and 93%, respectively, **Scheme 1**)




**Scheme 1.** Diastereoselective tandem Petasis 3-component/Diels-Alder cascade for the synthesis of tricyclic scaffold (**1a-b**); oxidative cleavage followed by reduction or reductive cyclization to bicyclic scaffold (**2a-b**) and tricyclic scaffold (**3a-d**).

The Diels-Alder products **1a** and **1b** were oxidatively cleaved using catalytic K<sub>2</sub>OsO<sub>4</sub> and NMO as oxidant,<sup>10</sup> followed by treatment with NaIO<sub>4</sub>. The intermediate dialdehyde was then either reduced to give the diols **2a** and **2b** in excellent yields (88% and 82%, respectively over three steps), or used in a reductive cyclisation with a variable primary amine to give the compounds **3a-3d** in high yields (70–95%, over three steps).

With the two diols **2a** and **2b** in hand, conditions for the Mitsunobu cascade sequence were investigated. By applying di-*tert*-butyl azodicarboxylate (DBAD) and PPh<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub> at 10 °C, full conversion to the cyclized product was observed after 15 min, and the product **4** was isolated in near quantitative yield (>95%) (**Scheme 2**). DBAD was used as the azo-reagent to facilitate easy removal of the hydrazine by-products via acid treatment, improving the application for large-scale production of screening libraries.<sup>11</sup>

Having established an efficient protocol for the intramolecular Mitsunobu reaction, we wanted to investigate the possibility of a tandem intramolecular–intermolecular Mitsunobu cascade, which would enable simultaneous creation of the core scaffold and functionalization of the remaining alcohol. The reactions were conducted using either phthalimide or phenol along with three equivalents of DBAD and PPh<sub>3</sub>. The reactions with phthalimide as external nucleophile proceeded smoothly to give **6a** and **6b** in excellent yields (90% and >95%, respectively over two steps) after the deprotection with hydrazine. On the other hand, the use of phenol only gave 10% of the desired product, along with 90% of a di-Boc hydrazine side-product (from reaction with reduced DBAD).


The low selectivity of the aromatic alcohol addition was solved by changing the solvent to THF and employing an excess of the nucleophile (3 equiv.), which gave the desired compounds **5a** and **5b** in excellent yields (>95% and 87%, respectively) using either phenol or 3-hydroxy pyridine as nucleophile (**Scheme 2**).



**Scheme 2.** Tandem Mitsunobu reactions for the synthesis of cyclic ethers (**5a-b**), primary amines (**6a-b**), and pyrazoles (**7a-b**). <sup>a</sup>Reaction performed in CH<sub>2</sub>Cl<sub>2</sub>.

Having observed the efficient addition of di-Boc hydrazine in the Mitsunobu reaction, we investigated if this could be exploited as an entry to create more structural diversity in the resulting library. When the reaction was conducted in CH<sub>2</sub>Cl<sub>2</sub>, notably without the addition of an external nucleophile, full conversion to the hydrazine product was observed. The crude reaction mixture was subsequently treated with 1 M HCl in EtOH and a 1,3-dicarbonyl electrophile, thus giving 1,2-diazole substituted compounds **7a** and **7b** in good yields (73% and 65%, respectively over two steps).

The two scaffolds, containing either a free phenol (**3b-3d**) or a primary amine (**6a-6b**) were subsequently functionalized. The phenols **3b-3d** were alkylated with various alkyl halides in DMF using KOH as base to give ethers **8a-8c** in high yields (75–94%) (**Scheme 3**). The primary amines **6a** and **6b** were functionalized using either a sulphonyl chloride, acid chloride or isocyanate to give derivatives **9a-9c** in high yields (73–85%).<sup>12</sup>



**Scheme 3.** Alkylation of phenols **3b–3d** and functionalization of amines **6a** and **6b** with sulfonyl chloride, acid chloride, and an isocyanate.

By using benzyl protected building blocks, a small library was synthesized to validate the strategy for library production. Rewardingly, the benzyl group was smoothly removed using catalytic Pd/C with HCOONH<sub>4</sub> as the hydrogen source. The resulting secondary amines were subsequently decorated with a variety of appendage functionalities using either reductive amination, amide couplings, sulfonylation or urea formation (**Table 1**). This process readily provided 30 compounds from the two scaffolds based on appendages using the 3–4 diversity points. The compounds were purified using preparative HPLC to simulate a large library production, and the compounds were generally isolated in good yields (33–95%, over two steps).


The validated chemistry was subsequently used to produce a total of 1617 screening compounds for the European Lead

Factory. Library **A** (826 compounds) and library **B** (791 compounds) were both produced with a success rate of 90% in the final functionalization step. All compounds were purified by mass-directed preparative HPLC and obtained in purities exceeding 95%.

## Conclusions

In conclusion, we have developed an efficient strategy for the synthesis of two complex and sp<sup>3</sup>-rich scaffolds (Fsp<sup>3</sup>=0.57), with excellent potential for appendage diversification reactions at three or four reactive sites. The benzyl protected building blocks for library production were obtained in 3–4 synthetic steps in high-yielding reactions amenable to large-scale synthesis. The chemistry was validated, first through production of thirty screening compounds (**Table 1**), and subsequently through large-scale production of 1617 compounds for the European Lead Factory.

**Table 1.** Benzyl deprotection followed by library production.



<sup>1</sup>All library compounds were purified by preparative HPLC to simulate large library production. *Reagents and conditions.* a) 2.5–10 mol% Pd/C, HCOONH<sub>4</sub>, MeOH or EtOH, reflux, 1–6 h. b) RCHO, NaBH(OAc)<sub>3</sub>, DMF, rt, 8–16 h. c) RCOOH, TBUTU, DIPEA, DMF, rt, 1–16 h. d) RSO<sub>2</sub>Cl, DIPEA, DMF, 1–16 h. e) RNCO, DMF, 1–16 h.

## Acknowledgements

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115489, resources of which are composed

of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in-kind contribution. We also thank Caroline Gurcel, Luciane Adeikalam and Guillaume Ranty at Edliris for assistance in the purification of the final library compounds.

## References

- 1 B. Munos, *Nat. Rev. Drug Disc.* 2009, **8**, 9591; R. Macarron, M. N. Banks, D. Bojanic, D. J. Burns, D. A. Cirovic, T. Garyantes, D. V. S. Green, R. P. Hertzberg, W. P. Janzen, J. W. Paslay, U. Schopfer, G. S. Sittampalam, *Nat. Rev. Drug Discov.*, 2011, **10**, 188. L. M. Mayr, P. Fuerst, *J. Biomol. Screen.*, 2008, **13**, 443.
- 2 D. J. Payne, M. N. Gwynn, D. J. Holmes, D. L. Pompliano, *Nat. Rev. Drug. Discov.*, 2007, **6**, 29; S. Dandapani, L. A. Marcaurelle, *Nat. Chem. Biol.* 2010, **6**, 861.
- 3 F. Lovering, J. Bikker, C. J. Humblet, *Med. Chem.* 2009, **52**, 6752; F. Lovering, F. *Med. Chem. Commun.*, 2013, **4**, 515; A. Chuprina, O. Lukin, R. Demoiseaux, A. Buzko, A. Shivanyuk, *J. Chem. Inf. Model.*, 2010, **50**, 470; A. Nadin, C. Hattotuwagama, I. Churcher, *Angew. Chem. Int. Ed.* 2012, **51**, 1114.
- 4 S. L. Schreiber, *Science*, 2000, **287**, 1964; D. R. Spring, *Org. Biomol. Chem.* 2003, **1**, 3867; D. S. Tan, *Nat. Chem. Biol.*, 2005, **1**, 74; T. E. Nielsen, S. L. Schreiber, *Angew. Chem., Int. Ed.*, 2008, **47**, 48; A. Karawajczyk, F. Giordanetto, J. Benningshof, D. Hamza, T. Kalliokoski, K. Pouwer, R. Morgentin, A. Nelson, G. Müller, A. Piechot, D. Tzalis, *Drug. Discov. Today*, 2015, **20**, 1310; H. G. Laverty, K. M. Orrling, F. Giordanetto, M. Poinot, E. Ottow, T. W. Rijnders, D. Tzalis, *S. J. Med. Dev. Sci.*, 2015, **1**, 20.
- 5 For recent examples of libraries with a high degree of sp<sup>3</sup> character, see: M. J. Rawling, T. E. Storr, W. A. Bawazir, S. J. Cully, W. Lewis, M. S. I. T. Makki, I. R. Strutt, G. Jones, D. Hamza, R. A. Stockman, *Chem. Commun.*, 2015, **51**, 12867; I. Churcher, R. Doveston, D. Foley, S. Marsden, A. Nelson, *Chem. Commun.*, 2015, **51**, 11174. A. Nelson, D. Roche, *Bioorg. Med. Chem.*, 2015, **23**, 2607.
- 6 For early accounts, see: N. A. Petasis, I. Akritopoulou, *Tetrahedron Lett.* 1993, **34**, 583; G. Dyker, *Angew. Chem. Int. Ed.*, 1997, **36**, 1700; For reviews on the Petasis 3-CR, see: N. A. Petasis, N. A. In *Multicomponent Reactions*; J. Zhu, H. Bienaymé, Eds., Wiley-VCH: Weinheim, Germany, 2005, pp 199–223; Batey, R. A. In *Boronic Acids*; Hall, D. G., Ed., Wiley-VCH: Weinheim, Germany, 2005, pp 279–304; N. R. Candeias, F. Montalbano, P. M. S. D. Cal, P. M. P. Gois, *Chem. Rev.* 2010, **110**, 6169; N. Kumagai, G. Muncipinto, S. L. Schreiber, *Angew. Chem., Int. Ed.*, 2006, **45**, 3635.
- 7 For review on IMDA, see: K. Takao, R. Munakata, K. Tadanu, *Chem. Rev.* 2005, **105**, 4779.
- 8 T. Flagstad, M. R. Hansen, S. T. Le Quement, M. Givskov, T. E. Nielsen *ACS. Comb. Sci.*, 2015, **17**, 19; A. Cannillo, S. Norsikian, P. Retailleau, M. T. H. Dau, B. I. Iorga, J. Beau, *Chem. Eur. J.* 2013, **19**, 9127; A. Cannillo, S. Norsikian, M. T. H. Dau, P. Retailleau, B. I. Iorga, J. Beau, *Chem. Eur. J.*, 2014, **20**, 12133.
- 9 For early accounts, see: O. Mitsunobu, Yamada, Y. *Bulletin of the Chemical Society of Japan*, 1967, **40**, 2380; O. Mitsunobu, O. Eguchi, *Bull. Chem. Soc. Jpn.* 1971, **44**, 3427. For reviews on the Mitsunobu reaction see: K. C. K. Swamy, N. N. B. Kumar, E. Balaraman, and K. V. P. P. Kumar *Chem. Rev.* 2009, **109**, 2551; S. Fletcher, *Org. Chem. Front.*, 2015, **2**, 739.
- 10 V. Vanrheenen, R. C. Kelly, D. Y. Cha, *Tetrahedron Lett.* 1976, **17**, 1973.
- 11 M. Kiankarimi, R. Lowe, J. R. McCarthy, J. P. Whitten, *Tetrahedron Lett.*, 1999, **40**, 4497.
- 12 T. Kalliokoski, *ACS Comb. Sci.*, 2015, **17**, 600.
- 13 C. A. Lipinski, F. Lombardo, B. W. Dominy, P. J. Feeney, *Adv. Drug. Deliv. Rev.*, 1997, **23**, 3; T. W. Johnson, K. R. Dress, M. Edwards, *Bioorg. Med. Chem. Lett.* 2009, **19**, 5560.